These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

647 related items for PubMed ID: 30840361

  • 1. Unexpected significant findings non-related to prostate cancer identified using combined prostate-specific membrane antigen positron emission tomography/CT and diagnostic CT scan in primary staging for prostate cancer.
    McEwan L, McBean R, Yaxley J, Wong D.
    J Med Imaging Radiat Oncol; 2019 Jun; 63(3):318-323. PubMed ID: 30840361
    [Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Jun; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    Hofman MS, Murphy DG, Williams SG, Nzenza T, Herschtal A, Lourenco RA, Bailey DL, Budd R, Hicks RJ, Francis RJ, Lawrentschuk N.
    BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
    [Abstract] [Full Text] [Related]

  • 5. [68Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer.
    Hirmas N, Al-Ibraheem A, Herrmann K, Alsharif A, Muhsin H, Khader J, Al-Daghmin A, Salah S.
    Mol Imaging Biol; 2019 Jun; 21(3):574-581. PubMed ID: 30215174
    [Abstract] [Full Text] [Related]

  • 6. Risk of metastatic disease on 68 gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer.
    Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, Yaxley AJ, Gianduzzo T, Kua B, McEwan L, Wong D.
    BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
    [Abstract] [Full Text] [Related]

  • 7. Frusemide aids diagnostic interpretation of 68 Ga-PSMA positron emission tomography/CT in men with prostate cancer.
    Fennessy N, Lee J, Shin J, Ho B, Ali SA, Paschkewitz R, Emmett L.
    J Med Imaging Radiat Oncol; 2017 Dec; 61(6):739-744. PubMed ID: 28623852
    [Abstract] [Full Text] [Related]

  • 8. The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer.
    Koschel S, Murphy DG, Hofman MS, Wong LM.
    Curr Opin Urol; 2019 Nov; 29(6):569-577. PubMed ID: 31567440
    [Abstract] [Full Text] [Related]

  • 9. Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis.
    Chow KM, So WZ, Lee HJ, Lee A, Yap DWT, Takwoingi Y, Tay KJ, Tuan J, Thang SP, Lam W, Yuen J, Lawrentschuk N, Hofman MS, Murphy DG, Chen K.
    Eur Urol; 2023 Jul; 84(1):36-48. PubMed ID: 37032189
    [Abstract] [Full Text] [Related]

  • 10. 68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer.
    Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, Gildehaus FJ, Stief CG, Gratzke C, Fendler WP.
    Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345
    [Abstract] [Full Text] [Related]

  • 11. Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer.
    Schmuck S, Nordlohne S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, Ross TL, Bengel FM, Derlin T.
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):960-968. PubMed ID: 28280856
    [Abstract] [Full Text] [Related]

  • 12. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
    Lenis AT, Pooli A, Lec PM, Sadun TY, Johnson DC, Lebacle C, Fendler WP, Eiber M, Czernin J, Reiter RE, Calais J.
    Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
    [Abstract] [Full Text] [Related]

  • 13. Diagnostic accuracy of 68 Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of 68 Ga-PSMA PET to mpMRI.
    Scheltema MJ, Chang JI, Stricker PD, van Leeuwen PJ, Nguyen QA, Ho B, Delprado W, Lee J, Thompson JE, Cusick T, Spriensma AS, Siriwardana AR, Yuen C, Kooner R, Hruby G, O'Neill G, Emmett L.
    BJU Int; 2019 Nov; 124 Suppl 1():42-49. PubMed ID: 31287613
    [Abstract] [Full Text] [Related]

  • 14. Detection and localisation of primary prostate cancer using 68 gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology.
    Kalapara AA, Nzenza T, Pan HYC, Ballok Z, Ramdave S, O'Sullivan R, Ryan A, Cherk M, Hofman MS, Konety BR, Lawrentschuk N, Bolton D, Murphy DG, Grummet JP, Frydenberg M.
    BJU Int; 2020 Jul; 126(1):83-90. PubMed ID: 31260602
    [Abstract] [Full Text] [Related]

  • 15. Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.
    Kuten J, Mabjeesh NJ, Lerman H, Levine C, Barnes S, Even-Sapir E.
    Isr Med Assoc J; 2019 Feb; 21(2):100-104. PubMed ID: 30772960
    [Abstract] [Full Text] [Related]

  • 16. Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach.
    Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, Hawaux E, Limani K, Otte FX, Peltier A, Sideris S, Sirtaine N, Flamen P, van Velthoven R.
    BJU Int; 2017 Aug; 120(2):197-203. PubMed ID: 27981732
    [Abstract] [Full Text] [Related]

  • 17. Utility of Ga68 prostate-specific membrane antigen positron-emission tomography for pre-operative staging of high-risk prostate cancer in a prospective cohort.
    Tarr GP, Kashyap P, Dixit DD, Willams AK, Koya MP, Lim R.
    J Med Imaging Radiat Oncol; 2020 Feb; 64(1):78-86. PubMed ID: 31885207
    [Abstract] [Full Text] [Related]

  • 18. Flourodeoxyglucose positron emission tomography scan may be helpful in the case of ductal variant prostate cancer when prostate specific membrane antigen ligand positron emission tomography scan is negative.
    McEwan LM, Wong D, Yaxley J.
    J Med Imaging Radiat Oncol; 2017 Aug; 61(4):503-505. PubMed ID: 28349676
    [Abstract] [Full Text] [Related]

  • 19. The impact of [68Ga]PSMA I&T PET/CT on radiotherapy planning in patients with prostate cancer.
    Frenzel T, Tienken M, Abel M, Berliner C, Klutmann S, Beyersdorff D, Schwarz R, Krüll A, Bannas P.
    Strahlenther Onkol; 2018 Jul; 194(7):646-654. PubMed ID: 29572670
    [Abstract] [Full Text] [Related]

  • 20. Diagnostic performance of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography in intermediate and high risk prostate cancer.
    El Hajj A, Yacoub B, Mansour M, Khauli R, Bulbul M, Nassif S, Haidar MB.
    Medicine (Baltimore); 2019 Nov; 98(44):e17491. PubMed ID: 31689752
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.